Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
Blood (2019) 134 (Supplement_1): 126.
Currently there are no citedby results. Try again later.
